Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (51-60 of 250) with videos related to

Pageof 25
Sort By:
British Journal of Haematology|May 15, 2015
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosisMaria T Cibeira, Albert Oriol, Juan J Lahuerta, et al.
Medicina Clinica|January 22, 2011
Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemiaBlanca Xicoy, Josep María Ribera, Pilar Miralles, et al.
Haematologica|March 17, 2018
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utilityIrena Misiewicz-Krzeminska, Luis Antonio Corchete, Elizabeta A Rojas, et al.
European Journal of Haematology|December 29, 2019
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaRoman Hajek, Ludek Pour, Muhit Ozcan, et al.
Nuclear Medicine Communications|July 25, 2013
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatmentEva González-Barca, Miguel Canales, Montse Cortés, et al.
Haematologica|October 13, 2005
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trialJosep-María Ribera, Albert Oriol, Concepción Bethencourt, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Leukemia & Lymphoma|October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesXavier Leleu, Meral Beksac, Takaaki Chou, et al.
Genome Medicine|March 17, 2023
Automated prioritization of sick newborns for whole genome sequencing using clinical natural language processing and machine learningBennet Peterson, Edgar Javier Hernandez, Charlotte Hobbs, et al.
Pageof 25

Showing results (51-60 of 250) with videos related to

Sort By:
Pageof 25
British Journal of Haematology|May 15, 2015
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosisMaria T Cibeira, Albert Oriol, Juan J Lahuerta, et al.
Medicina Clinica|January 22, 2011
Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemiaBlanca Xicoy, Josep María Ribera, Pilar Miralles, et al.
Haematologica|March 17, 2018
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utilityIrena Misiewicz-Krzeminska, Luis Antonio Corchete, Elizabeta A Rojas, et al.
European Journal of Haematology|December 29, 2019
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaRoman Hajek, Ludek Pour, Muhit Ozcan, et al.
Nuclear Medicine Communications|July 25, 2013
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatmentEva González-Barca, Miguel Canales, Montse Cortés, et al.
Haematologica|October 13, 2005
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trialJosep-María Ribera, Albert Oriol, Concepción Bethencourt, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Leukemia & Lymphoma|October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesXavier Leleu, Meral Beksac, Takaaki Chou, et al.
Genome Medicine|March 17, 2023
Automated prioritization of sick newborns for whole genome sequencing using clinical natural language processing and machine learningBennet Peterson, Edgar Javier Hernandez, Charlotte Hobbs, et al.
Pageof 25